Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OptiNose Inc OPTN

Healthcare
OptiNose, Inc. is a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and... see more

Recent & Breaking News (NDAQ:OPTN)

Optinose Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program

GlobeNewswire July 13, 2022

Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program

GlobeNewswire July 8, 2022

Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis

GlobeNewswire June 13, 2022

Optinose Announces Departure of Chief Financial Officer

GlobeNewswire June 3, 2022

Optinose Reports First Quarter 2022 Financial Results and Operational Updates

GlobeNewswire May 12, 2022

Optinose Announces Reporting Date for First Quarter 2022 Financial Results

GlobeNewswire May 5, 2022

Optinose Announces Appointment of R. John Fletcher to the Board

GlobeNewswire April 26, 2022

Optinose to Present at the Needham Virtual Healthcare Conference

GlobeNewswire April 8, 2022

Optinose Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights

GlobeNewswire March 8, 2022

Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis

GlobeNewswire March 7, 2022

Optinose Announces Reporting Date for Fourth Quarter 2021 Financial Results

GlobeNewswire March 4, 2022

Optinose Announces Appointment of Two New Members to Board of Directors

GlobeNewswire December 13, 2021

Optinose to Present at the Piper Sandler Virtual Healthcare Conference

GlobeNewswire November 23, 2021

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 18, 2021

Optinose Announces Closing of $46.0 Million Public Offering of Common Stock

GlobeNewswire November 18, 2021

Optinose Announces Pricing of Public Offering of Common Stock

GlobeNewswire November 16, 2021

Optinose Announces Proposed Public Offering of Common Stock

GlobeNewswire November 15, 2021

Optinose Reports Third Quarter 2021 Financial Results and Recent Operational Highlights

GlobeNewswire November 15, 2021

Optinose Announces Reporting Date for Third Quarter 2021 Financial Results

GlobeNewswire November 10, 2021

Optinose Completes Patient Recruitment in Second Pivotal Trial for XHANCE in Chronic Sinusitis

GlobeNewswire October 28, 2021